Download MendeleyStructure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control.
Aronov, A.M., Tang, Q., Martinez-Botella, G., Bemis, G.W., Cao, J., Chen, G., Ewing, N.P., Ford, P.J., Germann, U.A., Green, J., Hale, M.R., Jacobs, M., Janetka, J.W., Maltais, F., Markland, W., Namchuk, M.N., Nanthakumar, S., Poondru, S., Straub, J., ter Haar, E., Xie, X.(2009) J Med Chem 52: 6362-6368
- PubMed: 19827834
- DOI: https://doi.org/10.1021/jm900630q
- Primary Citation of Related Structures:
3I4B, 3I5Z, 3I60 - PubMed Abstract:
The Ras/Raf/MEK/ERK signal transduction, an oncogenic pathway implicated in a variety of human cancers, is a key target in anticancer drug design. A novel series of pyrimidylpyrrole ERK inhibitors has been identified. Discovery of a conformational change for lead compound 2, when bound to ERK2 relative to antitarget GSK3, enabled structure-guided selectivity optimization, which led to the discovery of 11e, a potent, selective, and orally bioavailable inhibitor of ERK.
Organizational Affiliation:
Vertex Pharmaceuticals Inc., 130 Waverly Street, Cambridge, Massachusetts 02139-4242, USA. alex_aronov@vrtx.com
